About Us>Medical Advisory Board > Sara Hurvitz, MD

Sara Hurvitz, MD

Division Head, Hematology/Oncology & Professor of Medicine, Fred Hutchinson Cancer Center; Professor of Medicine, University of Washington School of Medicine



Dr. Hurvitz is board-certification in internal medicine, hematology, and medical oncology. She led the breast cancer clinical trials program at UCLA for 17 years and was medical director of the Jonsson Comprehensive Cancer Center until 2023, when she accepted a leadership position at the University of Washington/Fred Hutchinson Cancer Center.

Dr. Hurvitz has won numerous awards over the past few years, among them the Marni Levine Memorial Breast Cancer Research Award, 2008 through 2015, and the European Society of Medical Oncology Breast Cancer Award in 2023. She has an active clinical practice specializing in the treatment of women with breast cancer. She is involved in designing, implementing, and leading multiple national and international clinical trials testing new targeted therapies.


Expertise & Accolades


  • Hematology/Oncology


  • University of Southern California School of Medicine
    • Doctor of Medicine
  • University of California, Irvine
    • Bachelor of Arts in Psychology
    • Bachelor of Science in Biology


  • Fred Hutchinson Cancer Center (2023-Present)
    • Professor and senior vice president, clinical research division
  • University of Washington School of Medicine (2023-Present)
    • Professor and head, division of hematology/oncology
  • Jonsson Comprehensive Cancer Center (2009-2023)
    • Medical director, clinical research unit
  • David Geffen School of Medicine at UCLA (2002-2023)
    • Professor, division of hematology/oncology
    • Associate professor, division of hematology/oncology
    • Co-director, Santa Monica-UCLA Outpatient Oncology Practices
    • Director, breast oncology program
    • Health sciences assistant clinical professor of medicine
    • HS clinical instructor
    • HS clinical instructor and attending physician
    • Chief resident, internal medicine

Awards & Distinctions

  • European Society of Medical Oncology Breast Award for outstanding achievements in the breast cancer field, 2023
  • Top Doctors Los Angeles Magazine, 2021, 2022
  • UCLA Health “100 in 100” Trailblazing Women Honoree, 2020
  • America’s Most Honored Doctors, Top 1%, 2020
  • Best Doctors in America, 2019, 2020
  • Southern California Top Doctors, 2020
  • Castle Connolly Exceptional Women in Medicine, 2017-2021
  • Pasadena Magazine Top Doctor, 2017
  • Castle Connolly Top Doctor, California, 2014-2022
  • Top Women Southern California Super Doctors, 2011
  • Southern California Super Doctors, 2010-2022
  • Diana Gordon Jonsson Award for Clinical Excellence, 2011
  • Andrea Dembrowsky Award, UCLA Women’s Health Center, 2009
  • ASCO Young Investigator Award, 2007
  • ASCO Foundation Merit Award, 2006
  • 2nd place poster, department of medicine Research Day, UCLA, 2006
  • 3rd place poster, department of medicine Research Day, UCLA, 2005

Professional Memberships & Board Positions

  • European Society of Medical Oncology, 2019-Present
  • American College of Phsyicians, Fellow, 2012-Present
  • American Association for Cancer Research, 2004-Present
  • American Society of Clinical Oncology, 2003-Present
  • American College of Physicians, 2001-Present
  • American Society of Hematology, 2003-2006


  • Medford AJ, Moy B, Spring LM, et. al. Molecular residual disease in breast cancer: Detection and therapeutic interception. Clin Cancer Res. 2023
  • Jhaveri K, Eli LD, Wildiers H, et. al. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol 2023
  • Hurvitz SA, Kim SB, Chung WP, et. al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial. Annals of Oncology 2023
  • Hurvitz SA, Bardia A, Quiroga V, et. al. Neoadjuvant giredestrant plus palbociclib vs anastrozole plus palbociclib in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (coopERA Breast Cancer): a randomised, open-label, international, phase 2 study. Lancet Oncology, 2023
  • Polito L, Shim J, Hurvitz SA, et. al. Real-world first-line use of pertuzumab with different taxanes for human epidermal growth factor receptor 2-positive metastatic breast cancer: A comparative effectiveness study using US electronic health records. JCO Oncol Pract. 2023